poisar

Stocks · News reference

8-K filing — UroGen Pharma Ltd. (URGN)

SEC EDGAR

Filed: 2026-08-20 AccNo: 0001437749-26-028590 Size: 151 KB Item 8.01: Other Events

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

URGN
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

    Zacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.

    OPRTUROYAMGNURGNNGL
  2. Na

    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 19 new employees, with up to 117,100 ordinary shares issuable upon vesting over three years. The company also announced a strategic collaboration and investment agreement with IntraGel Therapeutics to access a biodegradable sustained-release gel platform and expand its uro-oncology and specialty cancer pipeline.

    URGN